Cost-Effectiveness, the QALY, and the evLYG - ICER
文章推薦指數: 80 %
The quality-adjusted life year (QALY) is the gold standard for measuring how well all different kinds of medical treatments lengthen and/or improve ... OurApproach/Methods&Process/Cost-Effectiveness,theQALY,andtheevLYG Cost-Effectiveness,theQALY,andtheevLYG Cost-Effectiveness,theQALY,andtheevLYG Cliniciansplayavitalroleinhelping individualpatients decidewhattreatmentisbestforthem.Incontrast,cost-effectivenessanalysislooksatevidencefor entirepatientpopulations,comparingthehealthbenefitsandeconomiccostsofdifferenttreatmentoptions.Thegoalofcost-effectivenessanalysisistohelpinformpolicysothattreatmentsthatimprovepatients’livesarerewardedfairly,whileneitherpatientsnorsocietyoverpaysforcarethatdoesn’tofferasignificantbenefittopatients. Whatfollowsisanexplanationofhowcost-effectivenessisappropriatelyusedthroughouttheUShealthsystem.Additionalrelatedmaterials,includingalegalbriefconfirmingthatcost-effectivenessanalysesareconsistentwiththeAmericanswithDisabilitiesAct,canbefoundinthesidebartotheright. TheQALY:RewardingtheCareThatMostImprovesPatients’Lives(InstituteforClinicalandEconomicReview)SpecialReport:BigPharmaWagesStealthWaronDrugPricing(Reuters)ICERAnalysesandPayerUseofCost-effectivenessResultsBasedonQALYandevLYGAreConsistentWithADAProtectionsforIndividualsWithDisabilities(EpsteinBecker&Green)TheQALY:RewardingtheCareThatMostImprovesPatients’Lives(InstituteforClinicalandEconomicReview)WhytheComingDebateOvertheQALYandDisabilityWillBeDifferent(TheJournalofLaw,Medicine&Ethics)ObscureModelPutsaPriceonGoodHealth–andDrivesDownDrugCosts(TheWallStreetJournal)ICERReferenceCaseforEconomicEvaluations(InstituteforClinicalandEconomicReview) TheQALYandtheEVLYG Thequality-adjustedlifeyear(QALY)istheacademicstandardformeasuringhowwellalldifferentkindsofmedicaltreatmentslengthenand/orimprovepatients’lives,andthereforethemetrichasservedasafundamentalcomponentofcost-effectivenessanalysesintheUSandaroundtheworldformorethan30years.Ifevidenceshowsthatatreatmenthelpslengthenlifeorimprovequalityoflife,thesebenefitsarecomprehensivelysummeduptocalculatehowmanyadditionalQALYsthetreatmentprovides,andthisaddedhealthbenefitisthencomparedtotheaddedhealthbenefitofothertreatmentsforthesamepatientpopulation. TocomplementtheuseoftheQALY,ICER’sreportsalsoincludeacalculationoftheEqualValueofLifeYearsGained(evLYG),whichevenlymeasuresanygainsinlengthoflife,regardlessofthetreatment’sabilitytoimprovepatients’qualityoflife.Inotherwords,ifatreatmentaddsayearoflifetoavulnerablepatientpopulation–whethertreatingindividualswithcancer,multiplesclerosis,diabetes,epilepsy,oraseverelifelongdisability–thattreatmentwillreceivethesameevLYGasadifferenttreatmentthataddsayearoflifeforhealthiermembersofthecommunity. Byunderstandingatreatment’scostperevLYG,aswellasitstraditionalcostperQALY,policymakerscantakeabroaderviewofcost-effectivenessandbereassuredthattheyareconsideringinformationthatposesnoriskofdiscriminationagainstanypatientgroup. SafeguardLanguagetoEnsuretheEthicalandAppropriateUseofQALY-BasedAnalysis DuetoconcernsfromsomemembersofthedisabilitycommunitythatpolicymakersmayimplementQALY-basedcost-effectivenessanalysesinamannerthathasthepotentialtobediscriminatory,ICERhasputforthformalanti-discriminationlanguagetoguideitsownwork,andtoensuretheappropriateuseofitsworkbyothers: Inconsideringcost-effectiveness,[thestate]cannotusecost-effectivenessanalysesthatusethecost-per-qualityadjustedlifeyearorsimilarmeasuretoidentifysubpopulationsforwhichatreatmentwouldbelesscost-effectiveduetoseverityofillness,age,orpre-existingdisability. Inaddition,foranyprescriptiondrugthatextendslife,the[state’s]analysisofcost-effectivenessmustnotemployameasureormetricwhichassignsareducedvaluetothelifeextensionprovidedbyatreatmentbasedonapre-existingdisabilityorchronichealthconditionoftheindividualswhomthetreatmentwouldbenefit. LongstandingandAppropriateUseofCost-Effectiveness Cost-effectivenessanalysishasalongtrackrecordinacademicworkdonebyresearchersacrosstheUSandinternationally.Itisthecornerstoneofresearchcomparingthevalueofdifferentdrugsandotherhealthcareinterventions.TheUSgovernmentdoesnotcurrentlynegotiatedrugprices,butcost-effectivenessusingtheQALYisusedbyfederalresearchersattheCDCandNIHtoevaluatequestionssuchaswhethernewpediatricvaccinesshouldberecommended. Asanonprofit,nonpartisanorganization,ICERproducespubliclyavailablecost-effectivenessreportsondrugstohelpinformpolicymaking.TheStateofNewYorkhasusedthesereportsasaninputintoitsMedicaidprogramofnegotiatingdrugprices,joiningmanyothergroupswhohavebeenusingICERreportsformorethan5years,includingtheVeterans’Administration,HarvardPilgrimHealthCare,BlueCrossBlueShieldofMassachusetts,UnitedHealthcare,Aetna,KaiserPermanente,andExpressScripts. Conclusion Americansdeservetoknowifatreatmentimprovesorharmspatients’qualityoflife.Tothrowoutcost-effectivenessistorejectpatients’livedexperience–anexperiencethathastaughtusthatqualityoflifeshouldserveastheguidetofairdrugpricingandfairpatientaccess. Weallwantgoodaccesstotreatmentthatcanhelpus.Anditiseasytounderstandtheconcernsofsomedisabilitygroupswhohavehistoricallyhadtofighthardforequalaccesstoservices.Truediscriminationagainstpeoplewithdisabilitiescontinuesinthiscountryandhappenseverydaywhenpeoplecan’taffordoraccessthecaretheyneed.Butafundamentalrealityisthat highpricesfordrugswithoutanyanchoringinhowwellthosedrugsactuallyworkisdrivingupoverallhealthcarecosts,andthosespiralingpricesleaddirectlytoreducedaccessandhigheroutofpocketcostsforallpatients. Especiallyforpeoplewithdisabilitieswhooftenhavemorehealthcareneeds. Cost-effectivenessshouldneverbethesolefactorindecidingfairpricingofhealthcareinterventions. Butrejectingitwouldonlyservetokeeppatientslockedintothestatusquo–abrokensystemwheredrugmakerschargewhateverpricetheylike,insurersrespondwithbarrierstoaccess,andpatientsstruggletoaffordandaccessthecaretheyneed.Thatwouldbeatrueethicaltragedyforournation. Patientsdeservebetter. BacktoTop Weusecookiesonourwebsitetogiveyouthemostrelevantexperiencebyrememberingyourpreferencesandrepeatvisits.Byclicking“AcceptAll”,youconsenttotheuseofALLthecookies.However,youmayvisit"CookieSettings"toprovideacontrolledconsent.CookieSettingsAcceptAllManageconsent Close PrivacyOverview Thiswebsiteusescookiestoimproveyourexperiencewhileyounavigatethroughthewebsite.Outofthese,thecookiesthatarecategorizedasnecessaryarestoredonyourbrowserastheyareessentialfortheworkingofbasicfunctionalitiesofthewebsite.Wealsousethird-partycookiesthathelpusanalyzeandunderstandhowyouusethiswebsite.Thesecookieswillbestoredinyourbrowseronlywithyourconsent.Youalsohavetheoptiontoopt-outofthesecookies.Butoptingoutofsomeofthesecookiesmayaffectyourbrowsingexperience. Necessary Necessary AlwaysEnabled Necessarycookiesareabsolutelyessentialforthewebsitetofunctionproperly.Thesecookiesensurebasicfunctionalitiesandsecurityfeaturesofthewebsite,anonymously. CookieDurationDescriptioncookielawinfo-checkbox-analytics11monthsThiscookieissetbyGDPRCookieConsentplugin.Thecookieisusedtostoretheuserconsentforthecookiesinthecategory"Analytics".cookielawinfo-checkbox-functional11monthsThecookieissetbyGDPRcookieconsenttorecordtheuserconsentforthecookiesinthecategory"Functional".cookielawinfo-checkbox-necessary11monthsThiscookieissetbyGDPRCookieConsentplugin.Thecookiesisusedtostoretheuserconsentforthecookiesinthecategory"Necessary".cookielawinfo-checkbox-others11monthsThiscookieissetbyGDPRCookieConsentplugin.Thecookieisusedtostoretheuserconsentforthecookiesinthecategory"Other.cookielawinfo-checkbox-performance11monthsThiscookieissetbyGDPRCookieConsentplugin.Thecookieisusedtostoretheuserconsentforthecookiesinthecategory"Performance".viewed_cookie_policy11monthsThecookieissetbytheGDPRCookieConsentpluginandisusedtostorewhetherornotuserhasconsentedtotheuseofcookies.Itdoesnotstoreanypersonaldata. Functional Functional Functionalcookieshelptoperformcertainfunctionalitieslikesharingthecontentofthewebsiteonsocialmediaplatforms,collectfeedbacks,andotherthird-partyfeatures. Performance Performance Performancecookiesareusedtounderstandandanalyzethekeyperformanceindexesofthewebsitewhichhelpsindeliveringabetteruserexperienceforthevisitors. Analytics Analytics Analyticalcookiesareusedtounderstandhowvisitorsinteractwiththewebsite.Thesecookieshelpprovideinformationonmetricsthenumberofvisitors,bouncerate,trafficsource,etc. Advertisement Advertisement Advertisementcookiesareusedtoprovidevisitorswithrelevantadsandmarketingcampaigns.Thesecookiestrackvisitorsacrosswebsitesandcollectinformationtoprovidecustomizedads. Others Others Otheruncategorizedcookiesarethosethatarebeinganalyzedandhavenotbeenclassifiedintoacategoryasyet. SAVE&ACCEPT
延伸文章資訊
- 1淺談合理藥價制定分析方法——以阿茲海默症Aduhelm新藥為例
遞增成本效果比值(Incremental cost-effectiveness ratio,ICER) 為其 ... 公式為CUA = △C / QALY,也就是說以每增加一QALY 需要增加多...
- 2Incremental cost-effectiveness ratio - Wikipedia
A common application of the ICER is in cost-utility analysis, in which case the ICER is synonymou...
- 3Incremental Cost-Effectiveness Ratio (ICER) - YHEC
In the UK the QALY is most frequently used as the measure of health effect, enabling ICERs to be ...
- 4戒菸治療之成本效果分析
【公式】拯救一年生活品質調整生命年數(QALY)成本 ... 1 QALY = 1 year x. Perfect health. (score of 1). 0.8 QALY = ... (I...
- 52020-05-29 - 社團法人台灣藥物經濟暨效果研究學會
認識ICER(incremental cost-effectiveness ratio)已經數十寒暑,在學校教 ... 通常HTA機構都會要求評估報告內的健康結果incremental effe...